Allogene Therapeutics, Inc. announced the resignation of Eric Schmidt, Ph.D as principal financial officer and principal accounting officer, effective at the close of business on August 2, 2023, to spend more time with his family.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.32 USD | -3.73% | -7.20% | -27.73% |
05-31 | Piper Sandler Starts Allogene Therapeutics With Overweight Rating, $11 Price Target | MT |
05-21 | Oppenheimer Trims Allogene Therapeutics Price Target to $13 From $14, Maintains Outperform Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.73% | 484M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+3.23% | 22.78B | |
-10.44% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- ALLO Stock
- News Allogene Therapeutics, Inc.
- Allogene Therapeutics, Inc. Announces Resignation of Eric Schmidt from Principal Financial Officer and Principal Accounting Officer, Effective from August 2, 2023